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Abstract
Purpose of review Chest pain is a common presentation, and there are a wide variety of ways in
which it can be investigated and treated. There is growing interest inwhether thewaywe reach a
diagnosis of angina can affect the long-term prognosis. In addition to its unparalleled negative
predictive value, computed tomography coronary angiography (CCTA) gives anatomical infor-
mation on the extent and severity of coronary artery disease. This article discusses recent
research into the ability of CCTA to predict and improve long-term prognosis for patients with
stable angina.
Recent findings Results from retrospective studies, randomised controlled trials and meta-
analyses all suggest that initial investigation with computed tomography coronary angiography
confers a prognostic benefit. In addition, the most recent studies have shown that the
assessment of plaque burden and plaque constituents is predictive of long-term outcomes.
Summary Management of stable chest pain should be guided by a CCTA-based approach. Future
research should focus on whether incorporating plaque analysis strategies into clinical practice
confers additional benefit.
Introduction
To improve upon prognosis, one mustmake an accurate
diagnosis. The term prognosis was coined by Hippocra-
tes, to mean “foreseeing and foretelling” [1]. When doc-
tors give a prognostic statement, they predict the future
course of an individual’s condition. However, in order
to precisely predict the prognosis in any individual, it is
vital that an accurate diagnosis is made. A diagnosis
traditionally identifies a person as having or not having
a disease. Accurate diagnosis and acknowledgement that
there is a prognostic spectrum dependent on the severity
of disease are important and can focus treatments on
those who stand to gain the most benefit [2]. There is
growing interest in how improved diagnosis can posi-
tively impact upon prognosis. In those with chest pain
for example, accurate diagnosis of the presence and
severity of coronary artery disease has the potential to
alter management and improve outcomes. This article
will discuss the role of computed tomography coronary
angiography (CCTA) in assessing and improving the
long-term prognosis of patients with stable angina.
Improving prognosis for patients with stable angina
To understand how CCTA can affect the long-term prognosis of patients with
stable angina, we need to understand how it is managed. Chest pain is a
common presenting complaint, contributing nearly 4% of all new consulta-
tions to general practitioners [3]. A health survey for England estimated that
14% ofmen and 8% of women between the ages of 65 and 74 have or have had
angina [4]. Whilst large-scale epidemiological studies have shown beyond any
doubt that managing risk factors such as hypertension are prognostic, [5, 6].
views on more aggressive treatments are more divided.
Historically, stenoses deemed ‘significant’ (visually or due to the presence of
ischaemia on testing) would be treated with revascularisation—a treatment with
proven prognostic benefit in acute myocardial infarction [7]. Early studies on
coronary artery bypass grafting versusmedical therapy support this strategy, though
theywere conducted in an era before statin therapy [8]. Data from the Reduction in
Atherothombosis for ContinuedHealth (REACH) registry also suggested that those
with stable angina who had undergone revascularisation appeared to do better
than those who did not [9]. However, this was not substantiated in prospective
randomised trials. The Optimal Medical Therapy with or without PCI for Stable
CoronaryDisease (COURAGE) [10]. trial, andmore recently, the Initial Invasive or
Conservative Strategy for Stable Coronary Disease (ISCHAEMIA) [11]. both found
that even in the presence of severe ischaemia, there was no prognostic benefit to
utilising revascularisation. Ensuring that those with stable angina are on optimal
medical therapy is therefore of critical importance.
Today, there is a plethora of investigations available for patients with stable
angina, and each technique has unique benefits. Thus, it can be difficult to decide
which test is best as a first line, with even international guidelines presenting
conflicting recommendations (Table 1) [4, 12–14]. When selecting a diagnostic test,
equal emphasis should be placed on the ability to accurately determine presence or
absence of disease, the ability to quantify the severity and extent of disease and the
overall impact on patient care and prognosis. CCTA is an anatomical test which can
assess the presence and extent of coronary artery disease, identify coronary artery
stenoses and characterise the constituents of atherosclerotic plaque. In addition,
CTCA can provide additional functional information through the assessment CT
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fractional flow reserve (CT-FFR). Thus, CCTA offers the opportunity to identify a
range of potentially prognostic aspects of coronary atherosclerotic plaque.
CCTA to assess the severity and characteristics of coronary artery
disease
Multiple studies have established the excellent diagnostic accuracy of CCTA
compared to invasive coronary angiography to identify coronary artery stenoses
[15, 16]. The highly negative predictive value means that it is particularly useful
for ruling out coronary artery disease in patients with low to intermediate pre-
test probability [17]. CCTA is also very accurate at excluding high-risk distribu-
tion of coronary artery disease (left main stem and/or three vessel disease), with
a sensitivity of 95% and specificity of 83% [18]. In the Coronary CT Angiogra-
phy Evaluation for Clinical Outcomes: An International Multicentre
(CONFIRM) registry of 27,125 patients, the presence and severity of coronary
artery disease on CCTA were predictive of all-cause mortality [19]. Indeed, the
Table 1. Comparison of guideline recommendations for non-invasive investigation of stable chest pain
NICE (2016) [4] ESC (2019) [12] ACC/AHA (2012) [13, 14]
Initial
assessment
Assessment based on clinical
likelihood. Heavy reliance






Assessment based on pre-test
probability and clinical
likelihood.












If likelihood of CAD
low/intermediate, suggest
exercise ECG. If exercise










results are of uncertain
significance consider
alternative depending on
what is available locally.
Recommends CT coronary
angiography as an alternative






In cases with known CAD and
worsening symptoms
offer non-invasive
functional testing if there
is uncertainty about
symptom aetiology.
In cases with known CAD and
worsening symptoms offer
exercise ECG or non-invasive
functional imaging.
In cases with known CAD and
worsening symptoms offer
exercise ECG or non-invasive
functional imaging.
NICE National Institute for health and Care Excellence, ESC European Society of Cardiology, ACC/AHA American College of Cardiology/American
Heart Association, CAD coronary artery disease
Non-invasive functional imaging refers to stress echocardiography, myocardial perfusion scanning and stress perfusion cardiac magnetic
resonance imaging
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prognostic ability of CCTA has been shown to extend beyond 10 years [20•]
However, CCTA can identify both the presence of coronary artery stenoses and
the presence of non-obstructive coronary artery disease.
CCTA allows accurate quantification of plaque burden which has been
shown to improve the ability to risk stratify patients when added to conven-
tional angiographic assessment (Fig. 1) [21]. In a study of 3242 patients
undergoing CCTA, Bittencourt et al. showed that the extent of plaque on CCTA
enhances risk assessment for patientswith both obstructive and non-obstructive
disease [22]. For patients with non-obstructive disease in the CONFIRM regis-
try, the extent of coronary artery disease provided more prognostic information
than traditional cardiovascular risk factors [23]. CCTA also provides additive
prognostic information in older patients (9 70 years old), in whom CCTA has
previously been avoided due to the prevalence of heavily calcified plaques.
Indeed, the importance of quantifying the extent of nonobstructive disease
should not be overlooked, given that a diagnosis of multivessel nonobstructive
disease confers a similar prognosis to single-vessel obstructive disease [24].
CCTA not only provides information on anatomy, but can also be
used to gain functional information on the significance of coronary
artery stenoses. CT-FFR calculated from CCTA using computational fluid
dynamic techniques has been shown to improve the accuracy of identi-
fying haemodynamically significant coronary artery disease [25]. In the
Prospective LongitudinAl Trial of FFRct: Outcome and Resource Impacts
(PLATFORM) study and the Assessing Diagnostic Value of Non-invasive
FFR-CT in Coronary Care (ADVANCE) registry, [26]. CT-FFR led to lower
rates of invasive angiography showing no obstructive coronary artery
disease [27]. Similar to FFR measured during invasive coronary angiog-
raphy, a CT-FFR above 0.80 has been shown to be associated with a
good prognosis [28].
In addition to the burden of atherosclerotic plaque, particularly sub-
types of plaque have been shown to confer a worse prognosis. Non-
calcified plaque on CCTA is associated with a worse prognosis compared
to calcified plaque [29, 30]. Visual assessment can identify high-risk
plaque characteristics such as positive remodelling, low attenuation
plaque, spotty calcification and the napkin ring sign, which suggest
histological instability and are associated with a worse prognosis [31–
34]. In the Prospective Multicentre Imaging Study for Evaluation of
Chest Pain (PROMISE) trial, the presence of high-risk plaques was
associated with an increased risk of major adverse cardiovascular events
(hazard ratio (HR) 1.72; 95% CI 1.13 to 2.62, after adjustment for
cardiovascular risk and presence of significant stenoses) [35]. However,
in the Scottish COmputed Tomography of the HEART (SCOT-HEART)
trial, although high-risk plaques were associated with a worse prognosis,
this was not independent of coronary artery calcium score, a marker of
overall plaque burden [36].
It is now also possible to perform quantitative assessment of atherosclerotic
plaque subtypes on CCTA. In the Incidental Coronary EveNts Identified by
Computed Tomography (ICONIC) registry, quantitative plaque burden,
fibrofatty volume and necrotic core volume on CCTA were associated with risk
of subsequent ACS [37]. In the SCOT-HEART trial, quantitatively assessed low
attenuation plaque burden was the strongest predictor for fatal and non-fatal
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myocardial infarction (HR 1.6, 95%CI 1.10–2.34), over and above the presence
of coronary artery stenoses or coronary artery calcium score [38•]. These find-
ings challenge our preconceived ideas about the pre-eminence of coronary
Fig. 1. Plaque analysis using CCTA showing a an example of calcified plaque and b an example of mixed plaque. Calcified plaque is
highlighted in yellow and non-calcified plaque is highlighted in red.
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stenoses and highlight the importance of non-obstructive coronary artery dis-
ease in defining prognosis.
CCTA to clarify the diagnosis
Accurately identifying the presence of coronary artery disease has the po-
tential to alter diagnoses, and subsequently management, for patients with
stable angina. Registry studies have established the ability of CCTA to
reclassify patients compared to clinical risk scores in up to two thirds of
patients [20•]. In the SCOT-HEART [39]. trial, a large multicentre
randomised trial assessing the use of CCTA in patients presenting to the
chest pain clinic, CCTA clarified the diagnosis in one in four patients [40].
This was further corroborated by Foy and colleagues in their meta-analysis
which found that in comparison to functional testing, CCTA led to an
increase in coronary artery disease diagnosis and initiation of preventative
medications [41]. A further meta-analysis has demonstrated the greater
ability of CCTA to exclude atherosclerosis compared to stress testing [41].
By contrast, a negative functional test does not mean the patient is free from
non-obstructive coronary artery disease. CCTA therefore not only clarifies
the diagnosis, but also identifies those with sub-clinical disease who may
benefit from preventive therapies.
CCTA to improve prognosis
The 5-year outcomes of the SCOT-HEART trial provided the first evidence
that management based on CCTA findings could improve clinical out-
comes [42••]. In the SCOT-HEART trial, 4146 patients with stable chest
pain were randomised to either undergo CCTA or standard care (Table 2).
At 5 years, there was a significant reduction in the occurrence of fatal or
non-fatal myocardial infarction in patients whose management was guid-
ed by CCTA (HR 0.59; 95% confidence interval 0.41 to 0.84; p 0 0.004).
The improved prognosis was not driven by increased revascularisation,
but rather, the impact of increased medical therapy, particularly in the
group with non-obstructive coronary artery disease [46]. These findings
have been replicated in a real-world setting from a national Danish
registry [47]. Amongst 32,961 patients who underwent CCTA, there was
increased use of preventative medical therapy and a lower risk of myo-
cardial infarction (HR 0.71; 95% CI 0.61 to 0.82) [47]. Interestingly, in
the PROMISE study which compared CCTA with functional testing, al-
though there was no difference in outcomes between the two modalities
after 25 months, patients with more severe disease had a significantly
worse prognosis [45, 48].
An early criticism of CCTA was the potential to increase the use of invasive
coronary angiography. In the PROMISE trial, rates of referral for invasive
coronary angiography were higher in patients undergoing CCTA compared to
functional imaging, but those undergoing CCTAwere less likely to have normal
coronary arteries [45]. Furthermore, the 5-year results of SCOTHEART demon-
strated that with time, the rate of referral for invasive coronary angiography
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equalised [42••]. Thus, CCTA can be used to guide more appropriate and
timely use of invasive coronary angiography.
Whilst the ability of CCTA to reduce cardiovascular death and non-fatal
myocardial infarction has been discussed, one of the CCTA’s greatest strengths is
the ability to identify patients with normal coronary arteries. An interesting
finding from the SCOT-HEART study was that the greatest quality of life
improvements was seen in the cohort of patients who had normal coronary
arteries and did not require lifelong medical therapy [46].
Guidelines in the United Kingdom from the National Institute for health
and Care Excellence (NICE) are currently the only ones that recommend CCTA
as first-line assessment, doing away with pre-test probability calculations
(Table 1) [4, 12, 14].. A recent study by Houssany-Pissot and colleagues lends
Table 2. Outcomes from randomised controlled trials comparing an initial strategy of CCTA in patients with stable angina
Trial N Follow-up Comparison Outcome
Randomised Pilot Trial
[43] Min et al. (2012)
180 3 months Myocardial perfusion
imaging vs CCTA
• Equivalent improvements in
quality of life
• Increase incidence of aspirin (22% vs 8%,
p 0 0.04) and statin (7% vs − 3.5%, p 0
0.03) prescription with CCTA
• Lower total cost ($781.08 vs $1214.58,
p G 0.001) and radiation (7.4 mSv vs
13.3 mSv, p G 0.001) with CCTA
CAPP [44] Donnelly
et al. (2015)
500 1 year Exercise ECG vs CCTA • Improved control of angina symptoms
• Fewer patients required further
investigations (72 vs 128, p ≤ 0.0001)
with CCTA
• Increased revascularisation and
preventative medication with CCTA
• Reduced hospital re-attendance
(0.8% vs 5.2%, p 0 0.009)
PROMISE [45]
Douglas et al. (2015)
10,003 2 year Functional test
vs CCTA initially
• No difference in primary outcome of
major adverse cardiovascular event
(3.3% vs 3.0%, p 0 0.75) at 2 years
• Increase in invasive angiography
– Less likely to be normal
(3.4% vs 4.3%, p 0 0.02)
– More likely to lead to revascularisation
(3.2% vs 6.2%, p G 0.0001)
SCOT-HEART [39]
Newby et al. (2018)
4146 5 year Standard care vs CCTA • Significant difference in primary
outcome of cardiac death or
non-fatal myocardial infarction
(2.3% vs 3.9%, p 0 0.004).
• Equivalent rates of invasive angiography
and revascularisation by 5 years.
• Increased incidence of preventive and
anti-anginal therapies.
CCTA cardiac computed tomography angiography, mSv millisievert
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weight to this approach. They assessed nearly 5000 patients who underwent
invasive coronary angiography and found that CCTA was a better than func-
tional testing regardless of pre-test probability, limiting unnecessary down-
stream testing without missing abnormal invasive angiograms [49]. European
guidelines recommend CCTA for patients with low/intermediate pre-test prob-
ability and we await the updated ACC/AHA guidelines.
Conclusion
Randomised trials and real-world data show CCTA that can be used to assess
long-term prognosis in patients with stable angina. It provides the ability to
target optimal medical therapy and prognostic preventative medications to
those who will benefit from them. Moreover, invasive management can be
directed to those with disease in high-risk locations. In addition, novel tech-
niques can be used to qualitatively and quantitatively characterise high-risk
plaques. Management based on CCTA has been shown to improve long-term
outcomes and this is reflected in national and international guidelines.
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